Your shopping cart is currently empty

CLIK-148 is an oral, highly selective, irreversible inhibitor of cysteine protease that primarily targets cathepsin L. It effectively impedes the cathepsin L-dependent degradation of HMG-CoA reductase on the endoplasmic reticulum (ER) membrane. Additionally, CLIK-148 inhibits the cathepsin L-mediated processing of procholecystokinin (proCCK), leading to reduced production of CCK8. By obstructing cathepsin L degradation of type I collagen secreted by osteoclasts, CLIK-148 decreases tumor-induced bone metastasis and malignant hypercalcemia. This compound is valuable for research into bone metabolism disorders and neuropeptide processing regulation.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | CLIK-148 is an oral, highly selective, irreversible inhibitor of cysteine protease that primarily targets cathepsin L. It effectively impedes the cathepsin L-dependent degradation of HMG-CoA reductase on the endoplasmic reticulum (ER) membrane. Additionally, CLIK-148 inhibits the cathepsin L-mediated processing of procholecystokinin (proCCK), leading to reduced production of CCK8. By obstructing cathepsin L degradation of type I collagen secreted by osteoclasts, CLIK-148 decreases tumor-induced bone metastasis and malignant hypercalcemia. This compound is valuable for research into bone metabolism disorders and neuropeptide processing regulation. |
| In vitro | CLIK-148 at 100 nM to 10 μM concentration in rat liver effectively and specifically inhibits tissue Cathepsin L activity at 100 nM, shows almost no inhibition of Cathepsin B and C at 1 μM, and only weakly inhibits Cathepsin S and K at 10 μM. Additionally, CLIK-148 at 50 μM for 24 hours inhibits tissue Cathepsin L activity, blocking the conversion of proCCK to CCK9, and consequently reduces CCK8 production in pituitary AtT-20 cells. CLIK-148 at 1-10 nM for 72 hours efficiently prevents TNF-α-activated osteoclast-mediated bone collagen degradation in both human and mouse cells. Moreover, at 100 μM, CLIK-148 effectively protects HMG-CoA reductase from pathological degradation in C100 cells under necrotic damage conditions. |
| In vivo | CLIK-148, when administered intraperitoneally at doses of 1-10 mg/kg as a single treatment, significantly inhibits cathepsin L activity in mouse liver, without affecting cathepsin B activity. At 50 mg/kg orally, administered once daily for 7 days, it effectively prevents and treats tumor-induced malignant hypercalcemia in mice. Additionally, doses of 32-128 mg/kg administered orally or intravenously once daily for 7 days effectively suppress direct bone metastasis and local bone destruction by colon cancer cells. Furthermore, doses of 100-200 mg/kg taken orally once daily for 14 days specifically inhibit the process of cancer cell metastasis to bones via the bloodstream in mice. |
| Molecular Weight | 410.47 |
| Formula | C22H26N4O4 |
| Cas No. | 215098-90-1 |
| Smiles | C(N[C@@H](CC1=CC=CC=C1)C(N(C)C)=O)(=O)[C@@H]2[C@@H](C(NCCC3=CC=CC=N3)=O)O2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.